The strong clinical data across all three pipeline assets, particularly the first-in-class response in PDAC and the differentiated safety profiles, significantly de-risks the platform and could lead to partnership or acquisition interest. The 2028 cash runway provides ample time for pivotal data readouts in 2026, which could be major catalysts for the stock.
Price Chart
Executive Summary
BridgeBio Oncology Therapeutics (BBOT) reported its 2025 financial results and provided a corporate update, highlighting encouraging preliminary clinical data across its three RAS-pathway inhibitor programs. The company reported a net loss of $134.0 million for the year, with cash of $425.5 million providing a runway into 2028. Key clinical milestones include a 65% objective response rate for BBO-8520 in NSCLC, a first-in-class partial response for BBO-11818 in pancreatic cancer, and a differentiated safety profile for BBO-10203 with no hyperglycemia.
Key Financial Metrics
Key Facts
- Reported $425.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a runway into 2028.
- Net loss was $134.0 million for the year ended 2025, compared to $74.3 million in 2024.
- R&D expenses increased to $121.2 million in 2025 from $73.1 million in 2024.
- BBO-8520 monotherapy showed a 65% objective response rate in KRASG12C NSCLC patients.
- BBO-11818 produced the first publicly disclosed partial response in pancreatic ductal adenocarcinoma (PDAC) as a panKRAS inhibitor.
- BBO-10203 demonstrated a differentiated safety profile with no hyperglycemia and no baseline HbA1c restrictions.
- Clinical readouts for all three programs are expected in the second half of 2026.
Financial Impact
Net loss increased by $59.7 million year-over-year, while cash position grew by $269.8 million due to the de-SPAC transaction.
Risk Factors
- The company is pre-revenue and has a history of significant losses, which is expected to continue for the foreseeable future.
- The clinical data is preliminary, and later-stage trials may not replicate the observed efficacy or safety.
- The biotech sector is highly competitive, and other companies may develop superior RAS or PI3K inhibitors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-093997 |
| Document: bbot-20260305.htm | 0001193125-26-093997 |
| Document: 0001193125-26-093997-index-headers.html | 0001193125-26-093997 |
| Document: 0001193125-26-093997-index.html | 0001193125-26-093997 |
| Document: 0001193125-26-093997.txt | 0001193125-26-093997 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.69 (+45.66%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.69 (−60.18%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.69 (+70.24%) |
Aug 11, 2026 11w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.69 (−71.44%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.69 (−64.13%) |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.69 (−66.71%) |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.69 (−69.67%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.69 (−71.56%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.69 (−74.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers